Also in its Legacy portfolio, the company’s Q1 global Revlimid sales were $936M, down 44% y/y.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers reports Q1 EPS $1.80, consensus $1.50
- Bristol Myers raises FY25 EPS view to $6.70-$7.00 from $6.55-$6.85
- Options Volatility and Implied Earnings Moves Today, April 24, 2025
- Optimistic Buy Rating for Bristol-Myers Squibb Amid Low Valuation and Promising Pipeline
- Notable companies reporting before tomorrow’s open